Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel Modalities and Research Platforms

Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data across its oncology and hematology portfolio at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Related Keywords

United States ,Japan ,South Korea ,Taiwan ,American ,Pushkar Mutha ,Mariat Bourlon ,Tycel Jovelle Phillips ,Tony Mok ,Lin Wang ,Peter Robert Galle ,Charlene Mantia ,Marc Hoffmann ,Eric Christenson ,Suzanne Trudel ,Manali Kirtikumar Kamdar ,Guillermo Garcia Manero ,Martin Reck ,Tina Cascone ,Jonathan Spicer ,Elena Elimova ,Jeremy Abramson ,Bristol Myers Squibb ,Daniel Lin ,Williamg Wierda ,Andrewh Wei ,Ian Chau ,Francesco Passamonti ,Antonis Kattamis ,Claire Harrison ,Bertrand Arnulf ,Golcadomide Golca ,Clara Amorosi ,Paolo Antonio Ascierto ,Aimaz Afrough ,Kevin Kuo ,Steveny Liu ,David Valc ,Sheida Hayati ,Xavier Leleu ,Saby George ,Heinz Joseph Lenz ,Matthewd Galsky ,Esther Oliva ,Valeria Santini ,Manali Kamdar ,Michael Amatangelo ,Maria Teresa Voso ,Amer Methqal Zeidan ,Hemophagocytic Lymphohistiocytosis ,Luca Malcovati ,Mecide Meric Gharibo ,Jennifer Rachel Eads ,Michaela Postow ,Samit Hirawat ,Mark Pegram ,Daniel Halperin ,Sayed Matar ,Dirk Schadendorf ,John Cunningham ,Husseina Tawbi ,Julio Chavez ,Patrick Connor Johnson ,Omar Nadeem ,Xin Wang ,Alexander Drilon ,Hans Lee ,Kashyap Patel ,Instagram ,International Blood ,Facebook ,European Hematology Association ,Acceleron Pharma Inc ,Exchange Commission ,Laboratory Abnormalities ,Quality Care Health Services Research ,Linkedin ,Twitter ,American Society Of Clinical Oncology ,Drug Development ,Marrow Transplant Research ,Youtube ,Ono Pharmaceutical Co ,Drug Administration ,Clinical Oncology ,Annual Meeting ,Bristol Myers ,Important Safety Information ,Prescribing Information ,Boxed Warnings ,Acceleron Pharma ,Central Time ,Myeloid Leukemia ,Myelodysplastic Syndromes ,Lymphocytic Leukemia ,Chronic Lymphocytic Leukemia ,Hodgkin Lymphoma ,Expanded Access Protocol ,Small Cell Lung Cancer ,Previously Treated ,Metastatic Non Small Cell Lung Cancer ,Non Small Cell Lung Cancer ,Non Small Cell Metastatic ,Therapeutics Molecularly Targeted Agents ,Tumor Biology ,Cell Carcinoma ,Eastern Daylight ,Central European Time ,Myers Squibb ,Better Future ,Fatal Immune Mediated Adverse ,Full Prescribing Information ,Allogeneic Hematopoietic Stem Cell ,Multiple Myeloma ,Thalidomide Analogue ,Mediated Nephritis ,Drug Rash ,Adverse Reactions ,Release Syndrome ,Risk Evaluation ,Mitigation Strategy ,Neurologic Toxicities ,Macrophage Activation Syndrome ,Igg Secondary Malignancies ,Operate Machinery ,Lipase Elevation ,Product Characteristics ,Breakthrough Therapy Designations ,Orphan Drug ,Lung Disease ,Creatine Phosphokinase ,Ono Pharmaceutical ,Profit Share Agreement ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Current Reports ,Ihr Portfolio ,